Revance to Release Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
01 Agosto 2023 - 9:00AM
Business Wire
Conference Call Scheduled for Tuesday, August
8, 2023 at 4:30 p.m. ET.
Revance Therapeutics, Inc. (RVNC), today announced that the
company will release second quarter 2023 financial results on
Tuesday, August 8, 2023, after the close of market. Revance will
host a corresponding conference call and a live webcast at 1:30
p.m. PT / 4:30 p.m. ET on the same day to discuss the results and
provide a corporate update.
Individuals interested in listening to the conference call may
do so by dialing (888) 330-3637 for U.S. and Canadian callers, and
reference conference ID 5680588 or from the webcast link in the
investor relations section of the company's website at:
www.revance.com.
A webcast replay will be available beginning August 8, 2023, at
4.30 p.m. PT / 7.30 p.m. ET to November 9, 2023 at 4.30 p.m. PT /
7.30 p.m. ET. To access the replay, please register via the webcast
link on the events page. The webcast will be available in the
investor relations section on the company's website for 90 days
following the completion of the call.
About Revance
Revance is a biotechnology company setting the new standard in
healthcare with innovative aesthetic and therapeutic offerings that
elevate patient and physician experiences. Revance’s aesthetics
portfolio of expertly created products and services, including
DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection, the RHA®
Collection of dermal fillers, and OPUL®, the first-of-its-kind
Relational Commerce platform for aesthetic practices, deliver a
differentiated and exclusive offering for the company’s elite
practice partners and their consumers. Revance has also partnered
with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for
injection, which will compete in the existing short-acting
neuromodulator marketplace. Revance’s therapeutics pipeline is
currently focused on muscle movement disorders including evaluating
DAXXIFY® in two debilitating conditions, cervical dystonia and
upper limb spasticity.
Revance is headquartered in Nashville, Tennessee, with
additional office locations in Newark and Irvine, California. Learn
more at www.Revance.com, www.RevanceAesthetics.com,
www.DAXXIFY.com, or connect with us on LinkedIn.
“Revance” and the Revance logo, DAXXIFY®, and OPUL® are
registered trademarks of Revance Therapeutics, Inc.
Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE
SA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230801816173/en/
Investors Revance Therapeutics, Inc.: Jessica Serra,
510-279-6886 jessica.serra@revance.com or Gilmartin Group, LLC.:
Laurence Watts, 619-916-7620 laurence@gilmartinir.com
Media Revance Therapeutics, Inc.: Sara J. Fahy,
949-887-4476 sfahy@revance.com
Revance Therapeutics (NASDAQ:RVNC)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Revance Therapeutics (NASDAQ:RVNC)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
